Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: | Recruiting |
---|---|
Conditions: | Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Lymphoma, Hematology |
Therapuetic Areas: | Hematology, Oncology |
Healthy: | No |
Age Range: | 12 - 65 |
Updated: | 3/30/2019 |
Start Date: | November 2016 |
End Date: | December 2020 |
Contact: | Kelly Myers |
Email: | clinicaltrials@gamida-cell.com |
Phone: | +972-2-6595631 |
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
This study is an open-label, controlled, multicenter, international, Phase III, randomized
study of transplantation of NiCord® versus transplantation of one or two unmanipulated,
unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid
leukemia, myelodysplastic syndrome, chronic myeloid leukemia or lymphoma, all with required
disease features rendering them eligible for allogeneic transplantation.
study of transplantation of NiCord® versus transplantation of one or two unmanipulated,
unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid
leukemia, myelodysplastic syndrome, chronic myeloid leukemia or lymphoma, all with required
disease features rendering them eligible for allogeneic transplantation.
Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient
number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone
marrow and regenerating a full array of hematopoietic cell lineages with early and late
repopulating ability in a timely fashion.
A major drawback of Umbilical Cord Blood (UCB) is the low stem cell dose available for
transplantation, compared to mobilized peripheral blood (PB) or bone marrow. This low stem
cell dose can compromise the chances of engraftment and contributes to delayed kinetics of
neutrophil and platelet recovery, as well as other transplant outcomes.
The aim of ex vivo expansion of cord blood is to provide a graft with sufficient numbers of
cells that have rapid and robust in vivo neutrophil and platelet producing potential to
enable successful transplantation.
NiCord® is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic cells
from one entire unit of UCB. NiCord® utilizes the small molecule nicotinamide (NAM), as an
epigenetic approach to inhibit differentiation and to increase the migration, bone marrow
(BM) homing and engraftment efficiency of Hematopoietic Progenitor Cells (HPC) expanded in ex
vivo cultures. The chief aim of the study is to compare the safety and efficacy of NiCord®
single ex-vivo expanded cord blood unit transplantation to unmanipulated cord blood unit
transplantation in patients with hematological malignancies following conditioning therapy.
number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone
marrow and regenerating a full array of hematopoietic cell lineages with early and late
repopulating ability in a timely fashion.
A major drawback of Umbilical Cord Blood (UCB) is the low stem cell dose available for
transplantation, compared to mobilized peripheral blood (PB) or bone marrow. This low stem
cell dose can compromise the chances of engraftment and contributes to delayed kinetics of
neutrophil and platelet recovery, as well as other transplant outcomes.
The aim of ex vivo expansion of cord blood is to provide a graft with sufficient numbers of
cells that have rapid and robust in vivo neutrophil and platelet producing potential to
enable successful transplantation.
NiCord® is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic cells
from one entire unit of UCB. NiCord® utilizes the small molecule nicotinamide (NAM), as an
epigenetic approach to inhibit differentiation and to increase the migration, bone marrow
(BM) homing and engraftment efficiency of Hematopoietic Progenitor Cells (HPC) expanded in ex
vivo cultures. The chief aim of the study is to compare the safety and efficacy of NiCord®
single ex-vivo expanded cord blood unit transplantation to unmanipulated cord blood unit
transplantation in patients with hematological malignancies following conditioning therapy.
Inclusion Criteria:
- Applicable disease criteria
- Patients must have one or two partially HLA-matched CBUs
- Back-up stem cell source
- Adequate Karnofsky/Lansky Performance score
- Sufficient physiological reserves
- Signed written informed consent
Exclusion Criteria:
- HLA-matched donor able to donate
- Prior allogeneic HSCT
- Other active malignancy
- Active or uncontrolled infection
- Active/symptoms of central nervous system (CNS) disease
- Pregnancy or lactation
We found this trial at
19
sites
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Leonid Volodin, MD
Phone: 434-924-9333
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Richard Maziarz, MD
Phone: 503-494-4606
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Corey Cutler, MD
Phone: 617-851-2852
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Corey Cutler, MD
Phone: 617-851-2852
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials
Cleveland, Ohio
Principal Investigator: Rabi Hanna, MD
Phone: 216-444-0663
Click here to add this to my saved trials
1935 Medical District Dr
Dallas, Texas 75235
Dallas, Texas 75235
(214) 456-7000
Principal Investigator: Victor Aquino, MD
Phone: 214-456-2978
Children's Medical Center of Dallas Children's Medical Center is private, not-for-profit, and is the fifth-largest...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Mitchell Horwitz, MD
Phone: 919-668-1045
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Yasser Khaled, MD
Phone: 901-683-0055
Click here to add this to my saved trials
Click here to add this to my saved trials
Maywood, Illinois 60153
Principal Investigator: Patrick Stiff, MD
Phone: 708-327-3216
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Claudio Brunstein, MD
Phone: 612-625-3918
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Dennis Cooper, MD
Phone: 732-235-2465
Click here to add this to my saved trials
Click here to add this to my saved trials
Westwood, Kansas 66205
Principal Investigator: Joseph McGuirk, MD
Phone: 913-945-6591
Click here to add this to my saved trials